Low high-density lipoprotein cholesterol is not a risk factor for recurrent vascular events in patients with vascular disease on intensive lipid-lowering medication

Journal of the American College of Cardiology

Volumn 62, Issue 20, 2013, Pages 1834-1841

  Van De Woestijne, Anton P ^a   Van Der Graaf, Yolanda ^a   Liem, An Ho ^b   Cramer, Maarten J M ^a   Westerink, Jan ^a   Visseren, Frank L J ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b SINT FRANCISCUS GASTHUIS   (Netherlands)

Author keywords

HDL cholesterol; LDL cholesterol; secondary prevention; statins

Indexed keywords

ANTILIPEMIC AGENT; ATORVASTATIN; FLUINDOSTATIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN;

ADULT; ARTICLE; ATHEROSCLEROSIS; BODY MASS; CEREBROVASCULAR ACCIDENT; CHOLESTEROL BLOOD LEVEL; COHORT ANALYSIS; CORONARY ARTERY DISEASE; DRUG EFFICACY; FEMALE; FOLLOW UP; HEART INFARCTION; HUMAN; INTENSIVE CARE; LIPOLYSIS; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; RISK REDUCTION; VASCULAR DISEASE; WAIST CIRCUMFERENCE;

BMI; BODY MASS INDEX; CETP; CHOLESTERYL ESTER TRANSFER PROTEIN; CI; CONFIDENCE INTERVAL; HAZARD RATIO; HDL CHOLESTEROL; HDL-C; HIGH-DENSITY LIPOPROTEIN-CHOLESTEROL; HR; LDL CHOLESTEROL; LDL-C; LOW-DENSITY LIPOPROTEIN-CHOLESTEROL; SECONDARY PREVENTION; STATINS; TG; TRIGLYCERIDES;

AGED; ANTICHOLESTEREMIC AGENTS; CHOLESTEROL, HDL; CHOLESTEROL, LDL; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED; MYOCARDIAL ISCHEMIA; NETHERLANDS; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RECURRENCE; RISK FACTORS;

EID: 84887153834     PISSN: 07351097     EISSN: 15583597     Source Type: Journal    
DOI: 10.1016/j.jacc.2013.04.101     Document Type: Article

References (33)

1. W.P. Castelli, R.J. Garrison, P.W. Wilson, R.D. Abbott, S. Kalousdian, and W.B. Kannel Incidence of coronary heart disease and lipoprotein cholesterol levels. The Framingham Study JAMA 256 1986 2835 2838
2. A.R. Sharrett, C.M. Ballantyne, and S.A. Coady Coronary heart disease prediction from lipoprotein cholesterol levels, triglycerides, lipoprotein (a), apolipoproteins A-I and B, and HDL density subfractions - The Atherosclerosis Risk in Communities (ARIC) Study Circulation 104 2001 1108 1113
3. E. Di Angelantonio, N. Sarwar, and P. Perry Major lipids, apolipoproteins, and risk of vascular disease JAMA 302 2009 1993 2000
4. G.R. Hajer, Y. van der Graaf, M.L. Bots, A. Algra, and F.L. Visseren Low plasma HDL-c, a vascular risk factor in high risk patients independent of LDL-c Eur J Clin Invest 39 2009 680 688
5. J. Pekkanen, S. Linn, and G. Heiss Ten-year mortality from cardiovascular disease in relation to cholesterol level among men with and without preexisting cardiovascular disease N Engl J Med 322 1990 1700 1707
6. F.M. Sacks, A.M. Tonkin, and T. Craven Coronary heart disease in patients with low LDL-cholesterol: benefit of pravastatin in diabetics and enhanced role for HDL-cholesterol and triglycerides as risk factors Circulation 105 2002 1424 1428
7. J.C. Fruchart, F. Sacks, and M.P. Hermans The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in patients with dyslipidemia Am J Cardiol 102 2008 1 34K
8. S.M. Seo, E.H. Choo, and Y.S. Koh High-density lipoprotein cholesterol as a predictor of clinical outcomes in patients achieving low-density lipoprotein cholesterol targets with statins after percutaneous coronary intervention Heart 97 2011 1943 1950
9. P.M. Ridker, J. Genest, and S.M. Boekholdt HDL cholesterol and residual risk of first cardiovascular events after treatment with potent statin therapy: an analysis from the JUPITER trial Lancet 376 2010 333 339
10. C.H. Saely, A. Vonbank, and H. Drexel HDL cholesterol and residual risk of first cardiovascular events Lancet 376 2010 1738 1739
11. M.J. Chapman, H.N. Ginsberg, and P. Amarenco Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management Eur Heart J 32 2011 1345 1361
12. F.M. Sacks, L.A. Moye, and B.R. Davis Relationship between plasma LDL concentrations during treatment with pravastatin and recurrent coronary events in the Cholesterol and Recurrent Events trial Circulation 97 1998 1446 1452
13. K.K. Ray, C.P. Cannon, R. Cairns, D.A. Morrow, P.M. Ridker, and E. Braunwald Prognostic utility of apoB/AI, total cholesterol/HDL, non-HDL cholesterol, or hs-CRP as predictors of clinical risk in patients receiving statin therapy after acute coronary syndromes: results from PROVE IT-TIMI 22 Arterioscler Thromb Vasc Biol 29 2009 424 430
14. P. Natarajan, K.K. Ray, and C.P. Cannon High-density lipoprotein and coronary heart disease: current and future therapies J Am Coll Cardiol 55 2010 1283 1299
15. T.F. Luscher, S. Taddei, and J.C. Kaski Vascular effects and safety of dalcetrapib in patients with or at risk of coronary heart disease: the dal-VESSEL randomized clinical trial Eur Heart J 33 2012 857 865
16. G.G. Schwartz, A.G. Olsson, and M. Abt Effects of dalcetrapib in patients with a recent acute coronary syndrome N Engl J Med 367 2012 2089 2099
17. W.E. Boden, J.L. Probstfield, and T. Anderson Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy N Engl J Med 365 2011 2255 2267
18. HPS2 Collaborative Group. HPS2-THRIVE randomized placebo-controlled trial in 25,673 high-risk patients of ER niacin/laropiprant: trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment Eur Heart J 34 2013 1279 1291
19. HPS2-THRIVE Collaborative Group. Press release: Niacin causes serious unexpected side-effects, but no worthwhile benefits, for patients who are at increased risk of heart attacks and strokes. Available at: http://www. thrivestudy.org/press-release.htm. Accessed March 20, 2013.
20. P.C. Simons, A. Algra, M.F. van de Laak, D.E. Grobbee, and Y. van der Graaf Second manifestations of ARTerial disease (SMART) study: rationale and design Eur J Epidemiol 15 1999 773 781
21. A.J. Tremblay, H. Morrissette, J.M. Gagne, J. Bergeron, C. Gagne, and P. Couture Validation of the Friedewald formula for the determination of low-density lipoprotein cholesterol compared with beta-quantification in a large population Clin Biochem 37 2004 785 790
22. T.C. Weng, Y.H. Yang, S.J. Lin, and S.H. Tai A systematic review and meta-analysis on the therapeutic equivalence of statins J Clin Pharm Ther 35 2010 139 151
23. R. Hou, and A.C. Goldberg Lowering low-density lipoprotein cholesterol: statins, ezetimibe, bile acid sequestrants, and combinations: comparative efficacy and safety Endocrinol Metab Clin North Am 38 2009 79 97
24. D.P. Mikhailidis, R.W. Lawson, and A.L. McCormick Comparative efficacy of the addition of ezetimibe to statin vs statin titration in patients with hypercholesterolaemia: systematic review and meta-analysis Curr Med Res Opin 27 2011 1191 1210
25. Expert Panel on Detection Evaluation and Treatment of High Blood Cholesterol in Adults Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) JAMA 285 2001 2486 2497
26. Z. Reiner, A.L. Catapano, and G. De Backer ESC/EAS guidelines for the management of dyslipidaemias: the task force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS) Eur Heart J 32 2011 1769 1818
27. D. Duffy, D.N. Holmes, M.T. Roe, and E.D. Peterson The impact of high-density lipoprotein cholesterol levels on long-term outcomes after non-ST-elevation myocardial infarction Am Heart J 163 2012 705 713
28. P. Barter, A.M. Gotto, and J.C. LaRosa HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events N Engl J Med 357 2007 1301 1310
29. H. Drexel, S. Aczel, T. Marte, A. Vonbank, and C.H. Saely Factors predicting cardiovascular events in statin-treated diabetic and non-diabetic patients with coronary atherosclerosis Atherosclerosis 208 2010 484 489
30. E.M. deGoma, N.J. Leeper, and P.A. Heidenreich Clinical significance of high-density lipoprotein cholesterol in patients with low low-density lipoprotein cholesterol J Am Coll Cardiol 51 2008 49 55
31. B.F. Voight, G.M. Peloso, and M. Orho-Melander Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study Lancet 380 2012 572 580
32. P.J. Barter, M. Caulfield, and M. Eriksson Effects of torcetrapib in patients at high risk for coronary events N Engl J Med 357 2007 2109 2122
33. S. Yamashita, K. Tsubakio-Yamamoto, T. Ohama, Y. Nakagawa-Toyama, and M. Nishida Molecular mechanisms of HDL-cholesterol elevation by statins and its effects on HDL functions J Atheroscler Thromb 17 2010 436 451